Edwards Lifesciences Corporation logo
EWEdwards Lifesciences Corporation

Is the EV/Sales ratio high or low?

The EV/Sales ratio of 8.09x is 16% below its 5-year average of 9.63x, near the low end of its 5-year range (6.81x–16.04x).

As of Sunday, June 28, 2026. 4.82% above its 12-month average of 7.72x.

EV/EBITDA|P/S Ratio|Revenue|All Metrics
EW EV/Sales Ratio

EW EV/Sales Ratio Chart

8.09x
+4.39% 1Y
EW EV/Sales Ratio

EW Average EV/Sales Ratio Chart

EW EV/Sales Ratio

EW Current vs Average EV/Sales Ratio Chart

EW EV/Sales Ratio Metrics

EV/SALES RATIO

8.09x

EV/SALES RATIO AVG TTM

7.72x

EV/SALES RATIO AVG 3Y

7.75x

EV/SALES RATIO AVG 5Y

9.45x

EV/SALES RATIO AVG 10Y

9.67x

EV/SALES RATIO AVG 15Y

8.28x

EV/SALES RATIO AVG 20Y

7.17x

CURRENT VS TTM AVG

+4.82%

CURRENT VS 3Y AVG

+4.43%

CURRENT VS 5Y AVG

-14.43%

CURRENT VS 10Y AVG

-16.30%

CURRENT VS 15Y AVG

-2.27%

CURRENT VS 20Y AVG

+12.79%

EW Competitors' EV/Sales Ratio

NAMEMARKET CAPEV/SALES RATIOTTM3Y5Y
Edwards Lifesciences Corporation (EW)$52.27B8.09x7.72x7.75x9.45x
Cencora, Inc. (COR)vs ›$55.67B0.20x0.21x0.19x0.17x
Cardinal Health, Inc. (CAH)vs ›$55.72B0.24x0.21x0.16x0.14x
Becton, Dickinson and Company (BDX)vs ›$56.49B2.82x2.87x3.32x3.47x
Humana Inc. (HUM)vs ›$46.08B0.40x0.31x0.40x0.54x
IDEXX Laboratories, Inc. (IDXX)vs ›$43.50B10.21x12.30x11.48x12.31x
Regeneron Pharmaceuticals, Inc. (REGN)vs ›$65.20B4.55x5.04x6.53x6.18x
Boston Scientific Corporation (BSX)vs ›$65.74B3.67x7.19x7.76x7.04x
Agilent Technologies, Inc. (A)vs ›$38.41B5.56x5.55x5.75x6.18x
Medline Inc. (MDLN)vs ›$32.87B1.46x1.58x1.58x1.58x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

  • It works for unprofitable companies where P/E doesn't apply
  • Revenue is harder to manipulate than earnings
  • It supports comparisons across companies at different profitability stages
  • It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EV/Sales Ratio FAQ

What is the EV/Sales ratio for Edwards Lifesciences Corporation (EW)?
The EV/Sales ratio for EW stock is 8.09x.
Is Edwards Lifesciences Corporation's EV/Sales ratio high or low?
The EV/Sales ratio of 8.09x is 16% below its 5-year average of 9.63x, near the low end of its 5-year range (6.81x–16.04x).
What is the TTM average EV/Sales ratio for Edwards Lifesciences Corporation (EW)?
The TTM average EV/Sales ratio for EW stock is 7.72x.
What is the 3Y average EV/Sales ratio for Edwards Lifesciences Corporation (EW)?
The 3Y average EV/Sales ratio for EW stock is 7.75x.
What is the 5Y average EV/Sales ratio for Edwards Lifesciences Corporation (EW)?
The 5Y average EV/Sales ratio for EW stock is 9.45x.
What is the 10Y average EV/Sales ratio for Edwards Lifesciences Corporation (EW)?
The 10Y average EV/Sales ratio for EW stock is 9.67x.
What is the 15Y average EV/Sales ratio for Edwards Lifesciences Corporation (EW)?
The 15Y average EV/Sales ratio for EW stock is 8.28x.
What is the 20Y average EV/Sales ratio for Edwards Lifesciences Corporation (EW)?
The 20Y average EV/Sales ratio for EW stock is 7.17x.

EW EV/Sales Ratio History

DATEEV/SALES RATIO
2026-06-268.09x
2026-06-257.99x
2026-06-247.98x
2026-06-237.73x
2026-06-227.63x
2026-06-187.77x
2026-06-177.71x
2026-06-167.88x
2026-06-157.67x
2026-06-127.56x
2026-06-117.62x
2026-06-107.64x
2026-06-097.79x
2026-06-087.63x
2026-06-057.64x
2026-06-047.78x
2026-06-037.65x
2026-06-027.80x
2026-06-017.84x
2026-05-297.69x
2026-05-287.64x
2026-05-277.69x
2026-05-267.79x
2026-05-227.63x
2026-05-217.39x
2026-05-207.37x
2026-05-197.29x
2026-05-187.31x
2026-05-157.22x
2026-05-147.22x
2026-05-137.22x
2026-05-127.07x
2026-05-116.83x
2026-05-087.09x
2026-05-077.35x
2026-05-067.39x
2026-05-057.58x
2026-05-047.62x
2026-05-017.68x
2026-04-307.64x
2026-04-297.42x
2026-04-287.52x
2026-04-277.63x
2026-04-247.70x
2026-04-237.28x
2026-04-227.45x
2026-04-217.28x
2026-04-207.44x
2026-04-177.40x
2026-04-167.21x
2026-04-157.13x
2026-04-147.13x
2026-04-137.12x
2026-04-107.10x
2026-04-097.22x
2026-04-087.47x
2026-04-077.38x
2026-04-067.42x
2026-04-027.40x
2026-04-017.42x
2026-03-317.31x
2026-03-307.25x
2026-03-277.24x
2026-03-267.50x
2026-03-257.56x
2026-03-247.46x
2026-03-237.50x
2026-03-207.54x
2026-03-197.54x
2026-03-187.55x
2026-03-177.71x
2026-03-167.64x
2026-03-137.48x
2026-03-127.75x
2026-03-117.79x
2026-03-107.86x
2026-03-097.71x
2026-03-067.46x
2026-03-057.68x
2026-03-047.80x
2026-03-037.81x
2026-03-027.99x
2026-02-277.92x
2026-02-267.87x
2026-02-257.63x
2026-02-247.87x
2026-02-237.87x
2026-02-207.60x
2026-02-197.52x
2026-02-187.52x
2026-02-177.47x
2026-02-137.22x
2026-02-127.27x
2026-02-117.56x
2026-02-107.33x
2026-02-097.31x
2026-02-067.50x
2026-02-057.44x
2026-02-047.60x
2026-02-037.84x
2026-02-027.89x
2026-01-307.76x
2026-01-297.77x
2026-01-287.81x
2026-01-277.98x
2026-01-268.05x
2026-01-237.99x
2026-01-228.07x
2026-01-218.14x
2026-01-207.97x
2026-01-168.06x
2026-01-158.07x
2026-01-147.93x
2026-01-138.01x
2026-01-127.93x
2026-01-098.14x
2026-01-088.08x
2026-01-078.11x
2026-01-068.21x
2026-01-058.04x
2026-01-028.16x
2025-12-318.15x
2025-12-308.24x
2025-12-298.32x
2025-12-268.31x
2025-12-248.25x
2025-12-238.25x
2025-12-228.28x
2025-12-198.19x
2025-12-188.10x
2025-12-178.11x
2025-12-168.16x
2025-12-157.96x
2025-12-127.93x
2025-12-118.05x
2025-12-108.02x
2025-12-097.95x
2025-12-088.06x
2025-12-058.24x
2025-12-048.20x
2025-12-038.02x
2025-12-028.09x
2025-12-018.15x
2025-11-288.29x
2025-11-268.30x
2025-11-258.31x
2025-11-248.09x
2025-11-218.14x
2025-11-208.03x
2025-11-198.23x
2025-11-188.03x
2025-11-178.10x
2025-11-148.25x
2025-11-138.23x
2025-11-128.18x
2025-11-118.14x
2025-11-108.03x
2025-11-077.96x
2025-11-067.87x
2025-11-057.91x
2025-11-048.25x
2025-11-038.14x
2025-10-318.07x
2025-10-308.18x
2025-10-298.10x
2025-10-288.05x
2025-10-277.91x
2025-10-247.42x
2025-10-237.46x
2025-10-227.49x
2025-10-217.41x
2025-10-207.33x
2025-10-177.27x
2025-10-167.06x
2025-10-157.09x
2025-10-147.13x
2025-10-137.09x
2025-10-107.19x
2025-10-097.32x
2025-10-087.38x
2025-10-077.48x
2025-10-067.47x
2025-10-037.52x
2025-10-027.47x
2025-10-017.44x
2025-09-307.59x
2025-09-297.53x
2025-09-267.43x
2025-09-257.33x
2025-09-247.27x
2025-09-237.26x
2025-09-227.17x
2025-09-197.24x
2025-09-187.26x
2025-09-177.32x
2025-09-167.31x
2025-09-157.41x
2025-09-127.57x
2025-09-117.61x
2025-09-107.64x
2025-09-097.80x
2025-09-087.84x
2025-09-057.92x
2025-09-047.92x
2025-09-037.95x
2025-09-028.00x
2025-08-297.96x
2025-08-287.95x
2025-08-277.91x
2025-08-267.95x
2025-08-257.91x
2025-08-228.01x
2025-08-217.94x
2025-08-207.96x
2025-08-197.71x
2025-08-187.64x
2025-08-157.64x
2025-08-147.63x
2025-08-137.58x
2025-08-127.50x
2025-08-117.63x
2025-08-087.65x
2025-08-077.61x
2025-08-067.68x
2025-08-057.97x
2025-08-048.06x
2025-08-017.98x
2025-07-317.98x
2025-07-308.17x
2025-07-298.10x
2025-07-287.89x
2025-07-258.05x
2025-07-247.60x
2025-07-237.72x
2025-07-227.66x
2025-07-217.68x
2025-07-187.68x
2025-07-177.64x
2025-07-167.64x
2025-07-157.71x
2025-07-147.87x
2025-07-117.84x
2025-07-107.92x
2025-07-097.75x
2025-07-087.67x
2025-07-077.70x
2025-07-037.71x
2025-07-027.73x
2025-07-017.75x
2025-06-307.86x
2025-06-277.86x
2025-06-267.75x
2025-06-257.73x
2025-06-247.61x
2025-06-237.55x
2025-06-207.39x
2025-06-187.41x
2025-06-177.33x
2025-06-167.50x
2025-06-137.53x

Showing the most recent 260 of 5,032 data points. The chart above shows the full history.

Related Metrics

EV/EBITDAP/S RatioRevenueAll Metrics

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Irvine, CA
15,800 employees
www.edwards.com
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Bernard J. Zovighian
View full financials